Skip to main content
. 2021 Apr 5;11(4):315. doi: 10.3390/life11040315

Table 3.

Trials evaluating the reduction of cholesterol-LDL and cardiovascular risk in specific CKD populations.

Trial Population No. Patients Drug Follow-Up (Years) Ldl Reduction % Cv Event Reduction % p Value
SHARP CKD patients 9270 Simvastatin 20 mg/ ezetimibe 4.9 55% 17% 0.0021
4D Hemodialysis 1255 Atorvastatin 20 mg 4 42% - 0.35
AURORA Hemodialysis 2776 Rosuvastatin 10 mg 3.8 43% - 0.59

LDL: Low-density lipoprotein; CKD: Chronic Kidney Disease; CV: Cardiovascular; SHARP: Study of Heart and Renal Protection; 4D: Die Deutsche Diabetes Dialyse Studie; AURORA: An Assessment of Survival and Cardiovascular Events.